Maxigen Biotech (1783) Stock Overview

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical device and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates in two segments, Biomedical Products and Consumer Products. The company offers intra-articular injections under the ArtiAid, ArtiAid Plus, and ArtiBest names to treat osteoarthritis; Foramic, a bone substitute granule; FormaGraft, a bone graft substitute; GingivAid, a collagen dental grafts for use in dental implant surgery; and BestAid, a collagen bone graft. It also provides FormaAid, a guided tissue regeneration membrane; HealiAid, a collagen wound dressing product for dental and surgical use; PreviscAid, an ophthalmic viscoelastic device; BiVisc, an ophthalmic viscoelastic system; ViscAid, an ophthalmic viscoelastic device; and dermal filler injections under the Formaderm brand. In addition, the company engages in the manufacturing and sales of beauty care products. Maxigen Biotech Inc. was incorporated in 1998 and is headquartered in Taoyuan City, Taiwan.